CA2259965A1 - Hiv envelope polypeptides and vaccine - Google Patents

Hiv envelope polypeptides and vaccine Download PDF

Info

Publication number
CA2259965A1
CA2259965A1 CA002259965A CA2259965A CA2259965A1 CA 2259965 A1 CA2259965 A1 CA 2259965A1 CA 002259965 A CA002259965 A CA 002259965A CA 2259965 A CA2259965 A CA 2259965A CA 2259965 A1 CA2259965 A1 CA 2259965A1
Authority
CA
Canada
Prior art keywords
thr
asn
ile
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002259965A
Other languages
English (en)
French (fr)
Inventor
Phillip W. Berman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2259965A1 publication Critical patent/CA2259965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002259965A 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine Abandoned CA2259965A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
US08/676,737 1996-07-08

Publications (1)

Publication Number Publication Date
CA2259965A1 true CA2259965A1 (en) 1998-01-15

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259965A Abandoned CA2259965A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Country Status (13)

Country Link
US (1) US6090392A (enExample)
EP (1) EP0942988A1 (enExample)
JP (1) JP2000515368A (enExample)
AP (1) AP1282A (enExample)
AU (1) AU727107B2 (enExample)
CA (1) CA2259965A1 (enExample)
ID (1) ID17767A (enExample)
IL (2) IL127701A0 (enExample)
NZ (1) NZ333500A (enExample)
OA (1) OA10954A (enExample)
TW (1) TWI221846B (enExample)
WO (1) WO1998001564A1 (enExample)
ZA (1) ZA975889B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
WO2001083535A2 (en) * 2000-05-02 2001-11-08 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
US7754676B2 (en) 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7897152B2 (en) 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
EP1361886A2 (en) * 2001-02-15 2003-11-19 The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004110384A2 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
CA2577320C (en) * 2004-09-14 2019-08-13 Argos Therapeutics, Inc. Strain-independent amplification of pathogens and vaccines thereto
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
AU7676891A (en) * 1990-04-03 1991-10-30 Genentech Inc. Hiv envelope polypeptides
AU647108B2 (en) * 1990-04-03 1994-03-17 Genentech Inc. Methods and compositions for vaccination against HIV
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides

Also Published As

Publication number Publication date
NZ333500A (en) 2000-09-29
ID17767A (id) 1998-01-22
IL127701A0 (en) 1999-10-28
TWI221846B (en) 2004-10-11
US6090392A (en) 2000-07-18
AP1282A (en) 2004-06-09
WO1998001564A1 (en) 1998-01-15
JP2000515368A (ja) 2000-11-21
ZA975889B (en) 1998-02-23
AU3567797A (en) 1998-02-02
AU727107B2 (en) 2000-11-30
IL127701A (en) 2006-08-01
AP9901432A0 (en) 1999-03-31
OA10954A (en) 2001-10-25
EP0942988A1 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
US6090392A (en) HIV envelope polypeptides and vaccine
AU704309B2 (en) Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU709174B2 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV
EP0904380B1 (en) Synthetic hiv genes
US20030229214A1 (en) Vaccines comprising synthetic genes
US6544752B1 (en) Anigenically-marked non-infectious retrovirus-like particles
JP2000516445A (ja) 合成遺伝子を含むワクチン
CA2369119A1 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US7071322B2 (en) HIV envelope polynucleotides and immunogenic composition
US6121021A (en) Constitutive expression of non-infectious HIV-like particles
CA2338886C (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
CA2135200C (en) Canine coronavirus s gene and uses therefor
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
US20030087225A1 (en) Synthetic HIV genes
HK1046428A1 (zh) 1型人类免疫缺乏病毒(hiv-1)亚型间的基因组及其应用
HK1046428B (en) The genome of the hiv-1 inter-subtype (c/b') and use thereof
MXPA98006842A (en) Synthetic genes of

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued